Study of a Pandemic Influenza Vaccine in Elderly Participants

Seqirus

Status and phase: Completed; Phase 2

Conditions: Influenza

Treatments: Biological: H5N1 Pandemic Influenza Vaccine

Study type: Interventional

Funder types: Industry

Identifiers

NCT00376402

CSLCT-PAN-05-24

Details and patient eligibility

About

The World Health Organisation has warned that an influenza pandemic is inevitable. The avian influenza H5N1 virus strain is one of the leading candidates to cause the next influenza pandemic. The elderly are likely to be a special target group for vaccination; therefore, this study will test the safety and immunogenicity of a H5N1 pandemic influenza vaccine in a healthy elderly population.

Sex: All

Ages: 65+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male and female participants

Exclusion criteria

• History of clinically significant medical conditions
• History of Guillain-Barre syndrome or active neurological disease
• Resident of nursing home or long-term care facility

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind